Akoya Biosciences, Inc.

Akoya Biosciences, Inc. has not reported its direct greenhouse gas emissions data.

However, Akoya Biosciences, Inc. has demonstrated a commitment to climate action through its Science Based Targets initiative (SBTi) approved targets. The company has set a long-term net-zero target to achieve net-zero greenhouse gas emissions across its entire value chain by 2050.

For its near-term goals, Akoya Biosciences, Inc. aims to reduce Scope 1, 2, and 3 in-use operational GHG emissions of owned and leased buildings by 50% per square metre by 2030, from a 2023 base year. Additionally, it commits to reducing Scope 3 GHG emissions from purchased goods and services and capital goods by 51.6% per square metre within the same timeframe. The company also targets a 42% absolute reduction in Scope 3 GHG emissions from remaining purchased goods and services, fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, and employee commuting by 2030.

For its long-term targets, Akoya Biosciences, Inc. plans a 95.4% reduction per square metre in Scope 1, 2, and 3 in-use operational GHG emissions of owned and leased buildings by 2050, from a 2023 base year. It also commits to a 97% reduction per square metre in Scope 3 GHG emissions from purchased goods and services and capital goods by 2050. Furthermore, the company aims for a 99.6% absolute reduction in Scope 3 GHG emissions from remaining purchased goods and services, fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, and employee commuting by 2050. These targets are consistent with reductions required to keep warming to 1.5°C.